ActRIIB-Fc Fusion Protein for Bone Density and Side Effect Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for bone disorders such as osteoporosis and fractures often come with undesirable side effects, and there is a need for effective pharmaceutical agents that promote bone growth and increase bone density.
Innovation Solution
The use of an ActRIIB-Fc fusion protein, which acts as a dual anti-catabolic and anabolic agent by binding to activin A, activin AB, activin B, GDF11, and GDF8, promoting bone growth and increasing bone density through administration schedules that maintain serum concentrations between 8-20 µg/mL.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If current therapeutic agents for bone disorders are used, then bone growth and density can be improved, but undesirable side effects occur
Solution Approach 1:
The patent modifies the pharmacological parameters by using ActRIIB-Fc fusion protein with specific serum concentration ranges (8-20 µg/mL) and dosing intervals (once every 10-16 days) to achieve bone density improvement while minimizing side effects. The fusion protein's extended half-life and selective binding characteristics represent parameter changes that optimize the benefit-risk ratio.
2Strength
If bone resorption is inhibited, then bone density increases, but bone formation may be impaired
Solution Approach 1:
The ActRIIB-Fc fusion protein exhibits multi-functionality by simultaneously inhibiting bone resorption and promoting bone formation. The protein binds to multiple ligands (activin A, activin AB, activin B, GDF11, GDF8) that regulate both catabolic and anabolic bone processes, achieving a dual action that balances bone remodeling rather than simply inhibiting one aspect.
3Productivity
If ActRIIB-Fc fusion protein is administered at high concentrations, then bone density increases faster, but serum concentration control becomes difficult
Solution Approach 1:
The patent employs periodic dosing administration (once every 10-16 days) rather than continuous high-dose administration. This periodic action allows the fusion protein to reach therapeutic serum concentrations between doses while maintaining reliable control through scheduled dosing intervals, avoiding the complications of continuous high-concentration exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ActRIIB-Fc fusion protein effectively increases bone density and strength, providing a dual action that balances bone resorption and formation, thereby treating bone disorders and preventing bone damage caused by conditions like multiple myeloma and cancer metastases.
Implementation Method 1
binding to activin A, activin AB, activin B, GDF11, and GDF8
Data Source
Figure 1
Figure 2
Figure 3
AI summary
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided.